Regeneron Pharmaceuticals (REGN)
(Real Time Quote from BATS)
$963.76 USD
+8.00 (0.84%)
Updated May 9, 2024 10:37 AM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Regeneron (REGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1,032.63 | $1,189.00 | $720.00 | 8.04% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Regeneron comes to $1,032.63. The forecasts range from a low of $720.00 to a high of $1,189.00. The average price target represents an increase of 8.04% from the last closing price of $955.76.
Analyst Price Targets (21)
Broker Rating
Regeneron currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.56 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 18 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 72% and 4% of all recommendations. A month ago, Strong Buy made up 72%, while Buy represented 4%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 18 | 16 | 16 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 5 | 5 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.56 | 1.61 | 1.55 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
4/22/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
4/15/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
3/1/2024 | Not Identified | Not Identified | Not Available | Hold |
2/6/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
2/5/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Hold |
2/5/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
9/15/2023 | Argus Research Corp. | Jasper Hellweg | Not Available | Strong Buy |
8/21/2023 | Canaccord Genuity | John L Newman | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 25 |
Average Target Price | $1,032.63 |
LT Growth Rate | 13.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | 10.67 |